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Abstract
Cell replacement using stem cells is a promising therapeutic approach to treat degenerative motor neuron (MN) disorders,
such as amyotrophic lateral sclerosis and spinal cord injury. Human bone marrow-derived mesenchymal stem cells (hMSCs)
are a desirable cell source for autologous cell replacement therapy to treat nervous system injury due to their plasticity, low
immunogenicity, and a lower risk of tumor formation than embryonic stem cells. However, hMSCs are inefficient with
regards to differentiating into MN-like cells. To solve this limitation, we genetically engineered hMSCs to express MN-
associated transcription factors, Olig2 and Hb9, and then treat the hMSCs expressing Olig2 and Hb9 with optimal MN
induction medium (MNIM). This method of induction led to higher expression (.30% of total cells) of MN markers.
Electrophysiological data revealed that the induced hMSCs had the excitable properties of neurons and were able to form
functional connections with muscle fibers in vitro. Furthermore, when the induced hMSCs were transplanted into an injured
organotypic rat spinal cord slice culture, an ex vivo model of spinal cord injury, they exhibited characteristics of MNs. The
data strongly suggest that induced Olig2/Hb9-expressing hMSCs were clearly reprogrammed and directed toward a MN-like
lineage. We propose that methods to induce Olig2 and Hb9, followed by further induction with MNIM have therapeutic
potential for autologous cell replacement therapy to treat degenerative MN disorders.
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Introduction
Motor neurons (MNs) are essential effector cells for the control
of motor function. Degenerative MN diseases, such as amyo-
trophic lateral sclerosis (ALS) and spinal muscular atrophy, are
devastating disorders associated with loss of MNs [1,2]. Cell
replacement therapy using stem cells is a promising therapeutic
option for degenerative MN diseases because MNs located in
specific regions of the central nervous system have been linked to
these disorders [3,4]. Recent studies have demonstrated the in vitro
differentiation of human embryonic stem cells (hESCs) into MNs
[5]. However, the use of hESCs in clinical settings causes ethical
concerns and is hindered by safety issues, such as teratoma
formation and immune rejection [6,7]. In addition, feeder cells as
well as animal fetal calf sera that have been used to culture hESCs
pose safety concerns for clinical application [7].
Bone marrow-derived mesenchymal stem cells (MSCs) have
self-renewal capacity and are multipotent, with the capability to
differentiate into multiple mesodermal cells [8–10]. They can also
transdifferentiate into neuron-like cells, based on phenotype of
various neuronal markers and functional neuronal activity [11–
14]. Thus, due to their high plasticity and low immunogenicity,
human MSCs (hMSCs) could be ideal for autologous cell therapy
to treat the injured nervous system, including degenerative MN
diseases [15,16]. In addition, since MSCs do not appear to require
major histocompatibility match for transplantation, they could be
easily available in a clinical setting, which makes them considered
as ‘off-the-shelf stem cells’ for clinical application [17,18].
The transcriptional pathways that guide motoneuronal specifi-
cation during vertebral development have been well characterized
[19]. For example, transcription factors Olig2 and Hb9 are
essential for MN development and differentiation [20,21]. Basic
helix-loop-helix transcription factor Olig2 has been shown to be
important in the differentiation of oligodendrocytes and MNs in
vivo. Olig2 promotes MN development through repressing the
expression of antagonists of MN generation, such as Irx3, Scl and
other unidentified target genes [22]. Olig2 has a key role in
specifying pan-neuronal properties of developing MNs and is
selectively expressed by MN progenitors, and precedes the
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the homeodomain transcription factors MNR2 and Lim3 [21].
Expression of Olig2 also leads to the expression of post-mitotic
MN markers, including Islet-1 and Hb9, homeodomain transcrip-
tion factors, in neural progenitor cells [21]. Homeodomain
transcription factor Hb9 is expressed selectively in embryonic
MNs, and plays an essential role in MN development and
differentiation [20]. Hb9 triggers cell cycle exit, and an MN
marker Islet-1 expression in post-mitotic MN precursors [23].
It was reported that simultaneous expression of Olig2 and Hb9
could drive human adult olfactory neuroepithelial-derived pro-
genitors to differentiate into MNs in vitro [24]. Recent studies
reported on non-neural human somatic cells converting into
neurons by lineage-determining transcription factors, such as
Brn2, Ascl1, Myt1l, and NeuroD1 [25]. However, there is a gap in
the literature regarding the capability of hMSCs to differentiate
into MNs.
Recent studies demonstrated that various key lineage-specific
inducing factors have effects on differentiation into specific cell
types. The signaling molecule retinoic acid (RA) plays a key role in
neurogenesis [26–28]. Forskolin (FSK) increases intracellular
cAMP, and can promote axonal elongation [29,30]. Sonic
hedgehog (SHH) regulates the generation of MNs and dopami-
nergic neurons in the ventral region of the embryonic central
nervous system (CNS) [31,32]. RA and SHH are required to
regulate the expression of homeodomain and basic helix-loop-
helix transcription factors, which regulate the specification of MNs
in the ventral spinal cord [27,33–35].
Here, we test the hypothesis that hMSCs can be induced into
MN-like cells in a 2-step process. We ectopically expressed Olig2
and Hb9 in hMSCs and then induced with a motor neuron
induction medium (MNIM), which we developed in the labora-
tory. The simultaneous expression of these factors could facilitate
the induction of hMSCs into MN-like cells under an optimized
MNIM with RA, FSK and SHH. The induced Olig2/Hb9-
expressing hMSCs (EOH cells) showed marked expression of MN
markers. These induced hMSCs were also able to form functional
connections with muscle fibers in vitro. Furthermore, they could
maintain their neuron-like morphology and neuronal marker
expression even at 2 days after transplantation into the spinal cord
slice cultures. Our study provides a new fundamental basis for
autologous cell replacement therapy to treat degenerative MN
diseases.
Results
MN Induction of hMSCs
A previous study has reported that simultaneous expression of
Olig2 and Hb9 was sufficient to induce human olfactory
neuroepithelial progenitors to MN-like cells in vitro [24]. However,
as far as we are aware, there is no report that describes the
induction of hMSCs into MN-like cells. Thus, in this study, we
sought to develop an efficient protocol to generate MN-like cells is
partly depicted in Figure 1A.
We used a 2-step process to differentiate hMSCs into MN-like
cells. First, we ectopically expressed Olig2 and/or Hb9 in hMSCs
using EGFP-Olig2-Hb9 (EOH), EGFP-Olig2 (EO) and EGFP-
Hb9 (EH)-containing viral vectors. Control hMSCs were infected
with a virus containing vector alone (E). The transfectants were
then compared for MN differentiation. We determined whether
the expression of Olig2 and/or Hb9 induced the expression of
neuronal/motoneuronal marker genes in growth medium alone
(GM). We performed RT-PCR for Olig2, Hb9, neurofilament-M
(NF-M), Islet-1, and vesicular acetylcholine transporter (VAChT).
Olig2 mRNA was detected only in EO cells and EOH cells.
Likewise, Hb9 mRNA was detected only in EH cells and EOH
cells (Fig. 1B). However, there was no significant difference in the
mRNA levels of NF-M, Islet-1, and VAChT between the groups
(Fig. 1B), indicating that the expression of Olig2 and Hb9 were not
sufficient to induce the hMSCs to MN cells.
We next asked if MNIM treatment of the transfectants above
could differentiate the cells to MN cells. The cells were treated
with MNIM using the scheme shown in Figure 1A. The MNIM
protocol for hMSCs was developed in our laboratory based on the
previous studies of inducing hESCs to MN-like cells [5].
We also performed RT-PCR for Olig2, Hb9, NF-M, Islet-1,
and VAChT in MNIM-treated cells (Fig. 1B). Interestingly,
MNIM treatment significantly increased NF-M mRNA levels in all
groups (P,0.05) when compared with untreated cells (E) (Fig. 1B,
C). These results suggest that MNIM treatment is sufficient to
induce the expression of the neuronal marker gene, NF-M,i n
hMSCs. However, the mRNA for a MN marker, Islet-1, was only
significantly increased when MNIM was added to EO cells and
EOH cells (P,0.05) (Fig. 1B, D). Furthermore, we observed
a significant increase in the expression of another MN marker,
VAChT, only in MNIM-treated EOH cells (P,0.05) (Fig. 1B, E).
Although there was an increase in VAChT mRNA expression in
MNIM-treated EH cells, this increase did not reach statistical
significance (Fig. 1B, E).
In summary, NF-M, Islet-1, and VAChT mRNA levels were
increased significantly only in MNIM-treated EOH cells as
compared to untreated EOH cells. These results suggest that both
2-steps, including coexpression of Olig2 and Hb9 and MNIM
treatment, are required to induce hMSCs to MN-like cells.
Characterization of hMSCs Induced to MNs
Next, we further characterized the genetically engineered
hMSCs induced to MN-like cells (MNIM-EOH cells). First, we
examined whether there were morphological changes during
induction with MNIM. Untreated EOH cells exhibited a flattened
and symmetrical fibroblast-like morphology (Fig. 2A). However,
following exposure to MNIM, EOH cells underwent morpholog-
ical changes and adopted a neuron-like morphology (structures of
cell bodies with long thin processes) (Fig. 2B–D). Morphological
changes were apparent in ,7% of cells at day 5 post-induction
(Fig. 2B) and in .32% of cells at day 9 post-induction (Fig. 2C, D,
Table 1).
To determine whether the morphology of induced EOH cells
could be maintained without the inducing factors, we further
cultured fully induced cells in growth medium only. It has been
reported that cell-doubling time of hMSCs is 48 to 72 hours [36].
We also calculated the doubling time of uninduced EOH cells
(49.87 hours, Figure S1). Thus, we hypothesized that if cells were
not induced to neurons, they would undergo actin reorganization
for cell division during 2 days in growth medium instead of
maintaining neuron-like morphology. However, approximately
18% of the induced EOH cells still maintained neuron-like
morphology even after 2 days without MNIM (Fig. 2E, Table 1).
Thus, this morphological change was not due to actin re-
organization by the inducing factors since these cells could
maintain changed morphology for 2 days even without MNIM.
We also confirmed that Olig2 and Hb9 were still expressed in
these cells by immunocytochemistry as in uninduced EOH cells
(Fig. 2F).
We further characterized the cells by determining for the
expression of mature neuronal and MN-specific marker proteins,
neuronal nuclei (NeuN), NF-M, choline acetyltransferase
(ChAT), and Islet-1 in MNIM-EOH cells (Fig. 3A). Immunocy-
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M, ChAT, or Islet-1 protein expression was significantly
increased in MNIM-EOH cells (P,0.001) when compared with
uninduced EOH transfectants (GM), which expressed low to
undetectable levels of these markers (Fig. 3B). In induced EOH
cells further cultured in growth medium for 2 days after 9-day
complete induction (MNIM+GM), the percentages of NeuN, NF-
M, ChAT, or Islet-1-positive cells were much higher (.13% of
Figure 1. MN marker gene expression in hMSCs expressing Olig2 and Hb9 in the presence of MNIM. (A) Schematic illustration of the
protocol used for MN induction of hMSCs. (B) RT-PCR analyses of hMSCs expressing EGFP (E), EGFP-Olig2 (EO), EGFP-Hb9 (EH), and EGFP-Olig2-Hb9
(EOH) with MNIM treatment were preformed. Quantification of NF-M (C), Islet-1 (D), and VAChT (E) PCR products. The mRNA level of a given gene
was quantified by densitometry and normalized to the corresponding b-actin level. The bars represent mean6SEM of at least three independent
experiments. *P,0.05 versus uninduced E. The significance was determined by Mann-Whitney test with Fisher’s LSD post hoc test.
doi:10.1371/journal.pone.0035244.g001
Figure 2. Changes in cell morphology of hMSCs expressing Olig2-Hb9 after the induction. Bright-field images of uninduced EOH cells (A),
EOH cells induced for 5 days (B), completely induced EOH cells (C), and induced EOH cells further cultured in growth medium for 2 days after
complete induction (E). (D) A higher magnification of the corresponding box shown in (C). (F) GFP (green), Olig2 (blue) and Hb9 (red) were expressed
in EOH cells. Scale bar: 100 mm.
doi:10.1371/journal.pone.0035244.g002
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although, significantly lower than MNIM-EOH cells (Fig. 3B).
Taken together, these results indicate that EOH cells exposed to
MNIM adopted morphological and molecular markers, consis-
tent for MNs.
Cell Cycle Arrest Occurs in hMSCs Induced to MNs
Previously, we demonstrated that Schwann cell induction of
hMSCs was associated with cell-cycle arrest [37]. Thus, we
examined whether MN induction of hMSCs could also lead to
cell cycle arrest. This question was addressed in studies to
monitor bromodeoxyuridine (BrdU) incorporation (Fig. 3C).
The number of BrdU-incorporated cells was significantly
decreased in MNIM (21.4%62.1%) and MNIM+GM
(29.5%61.1%) compared to GM (45.4%64.4%) (P,0.05)
(Fig. 3D). These results indicate that the induction of hMSCs
to MN correlated with reduced cell cycling.
Excitable Properties of MNIM-EOH Cells
Neuronal properties of MNIM-treated EOH cells were
studied with perforated patch clamp recording in the voltage
clamp mode using a step protocol from 290 mV to +30 mV.
This protocol failed to elicit Na+ currents in EOH cells (Fig. 4A;
n=10/10), but elicited small inward Na+ currents in more than
a half of MNIM-EOH cells (Fig. 4B, triangles; 8 out of 11 cells).
These results suggest that although MNIM-EOH cells express
functional K+ channels, they express low levels of voltage-gated
Na+ channels. To further assess the excitable properties of
MNIM-EOH cells, we performed perforated patch clamp
recording in the current clamp mode. Resting membrane
potential of MNIM-EOH cells (n=11) ranged from 230 mV to
264 mV, and more than a half of these cells exhibited evoked
action potentials (n=8/11). In contrast, the membrane potential
of EOH cells (n=10/10) ranged from 229 mV to 248 mV,
and none of the cells exhibited evoked action potentials
(Fig. 4C). These results are consistent with their inability to
fire spontaneous or evoked action potentials. Taken together,
the results indicate that MNIM-EOH cells have the excitable
properties of neurons.
MNIM-EOH Cells can Induce AChR Clustering and Form
Functional Connections with Myotubes
The primary function of MNs is to trigger muscle contraction
by releasing Ach at the neuromuscular junction (NMJ). NMJs
contain acetylcholine receptor (AChR) clustering (reviewed in
[38]). To examine whether MNIM-EOH cells could form NMJs
with cocultured C2C12 myotubes, we determined if there is
colocalized EGFP+ axons with rhodamine conjugated a-bungar-
otoxin (a-BTX), which labels clustered AChRs. Indeed, AChR
clustering occurred on myotubes immediately adjacent to the
extended EGFP+ axons (Fig. 5A, arrow).
In order to determine whether MNIM-EOH cells can establish
functional connections with myotubes, we performed whole-cell
recordings from the individual myotubes. Four end-plate currents
(EPCs) were recorded from individual myotubes 9 days after
plating (Fig. 5B; a single EPC is indicated with an arrowhead).
EPCs were completely blocked from the same cell shortly after
bath application of pancuronium (15 mM for 5 min; n=4, Fig. 5B),
indicating that the EPCs were generated due to cholinergic
transmission. The data were supported by the full recovery of
EPCs after washing out of pancuronium (n=4, Fig. 5B).
Therefore, these results indicate that MNIM-EOH cells can
induce AChR clustering and form functional NMJs with myotubes
in vitro.
Ex Vivo Assessment of Transplanted MNIM-EOH Cells in
Demyelinated Organotypic Spinal Cord Slice Culture
The ex vivo properties of MNIM-EOH cells were studied after
transplantation into the lysolecithin-treated rat spinal cord slice
culture. Organotypic spinal cord slice cultures were prepared as
previously described by our group [37,39]. Although a number of
cellswerewashedawayduringthetransplantationprocedure,many
EGFP+cellswerefoundintheventralregionofthespinalcordslices
when examined even 2 days later (Fig. 6). Untreated EOH cells
maintained a flattened and symmetrical fibroblast-like morphology
in slices (Fig. 6A-C). However, MNIM-EOH cells could maintain
their differentiated neuron-like morphology in slices (Fig. 6D-F).
Furthermore, they seemed to be connected with adjacent neurons,
although it is not clear whether they had functional synapses.
We further investigated whether these transplanted MNIM-
EOH cells expressed mature neuronal and MN-specific marker
proteins. Immunohistochemical analysis indicated that , 8% of all
EGFP+ cells expressed a neuronal marker NeuN (Fig. 7A), and
,7% of all EGFP+ cells expressed NF-M (Fig. 7B) at 2mdays after
transplantation. Furthermore, ,3% of all EGFP+ cells expressed
an MN-specific marker ChAT (Fig. 7C). These results suggest that
MNIM-EOH cells can survive in the injured spinal cord slice
while maintaining expression of neuronal and MN-specific
markers.
Discussion
ESCs, by in vitro methods, can differentiate into functional
MNs when treated with SHH and RA [5,35,40]. However, the
potential for immune rejection and the possibility of teratoma
formation may limit clinical application. Our study demonstrates
that hMSCs can be induced into MN-like cells through genetic
engineering. Combined induction of Olig2 and Hb9, and
exposure to SHH and RA induced the generation of MN-like
cells in vitro. The efficiency of induction was 29–33% based on
MN-specific marker and morphological analyses. In addition,
approximately 18% of the induced EOH cells still maintained
neuron-like morphology even after 2 days without MNIM,
indicating that the morphological changes occurred during
induction with MNIM could be maintained in these cells. We
previously showed that the Schwann cell induction of hMSCs led
to cell cycle arrest during differentiation [37]. The current study
also demonstrated that cell cycle arrest occurred during the MN
induction.
The combination of RA and SHH stimulates the expression of
transcription factors which play important roles in neuronal
differentiation [27,33,34]. However, morphogens, including RA
Table 1. Quantitative analysis of cell morphology (% of total
cells).
MSC-like
morphology
Neuronal-like
morphology
Untreated EOH-hMSC 100 0
Day 3 post-induction 98.860.7 1.260.7
Day 5 post-induction 92.962.2 7.162.2
Induced EOH-hMSC 67.162.5 32.962.5
Induced EOH-hMSC+GM 82.262.7 17.862.7
The values are expressed as the mean6SEM.
doi:10.1371/journal.pone.0035244.t001
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stem cells or neural precursors [24,41,42]. Likewise, in this study,
RT-PCR analyses also demonstrated that SHH and RA had only
minimal effects on MN induction of hMSCs. For example,
MNIM-treated hMSCs without genetic modification, expressed
low mRNA levels of Islet-1 or VAChT. We also observed that only
a few cells exhibited a neuron-like morphology (data are not
shown). This suggests that the missing transcription factors are
required to drive in vitro MN differentiation of hMSCs because the
response of hMSCs to RA and SHH was incomplete.
Previously, it was reported that simultaneous transfection of
human olfactory neuroepithelial-derived progenitors with Olig2
and Hb9 combined with other factors lead to the expression of
MN lineage-restricted markers [24]. Genetically engineered fetal
rat neural precursors with transcription factors HB9, Nkx6.1, and
Neurogenin2 can also induce the generation of MNs in vitro in the
presence of RA and SHH [41]. In this study, we developed the
method to induce to MN-like cells from genetically engineered
hMSCs instead of neural progenitors or precursors, since we
believe that hMSCs have more therapeutic potential for
autologous cell replacement therapy to treat degenerative MN
disorders.
In this study, hMSCs ectopically expressing Olig2 and Hb9
have a significantly increased MN-specific marker expression and
the capacity to induce AChR clustering on myotubes after being
treated with MNIM, containing inducing factors. Consistent with
the roles of inducing factors that stimulate neurogenesis,
simultaneous expression of Olig2 and Hb9 cannot increase
Figure 3. Increased expression of mature neuronal/motoneuronal markers and cell-cycle arrest occur in MNIM-treated EOH cells.
(A) Immunocytochemistry analysis of neuronal and MN-specific markers in uninduced EOH cells, MNIM-EOH cells, and MNIM-EOH cells further
cultured in growth medium for 2 days after complete induction. Each row represents NeuN (red), NF-M (red), ChAT (red), and Islet-1 (red) staining
with EGFP (green). Scale bar: 50 mm. (B) Quantitative analysis of NeuN, NF-M, ChAT, and Islet-1 expression. Fifty to 150 cells per group were analyzed
in randomly chosen fields. The bars represent mean6SEM of at least three independent experiments. * P,0.05, ** P,0.001 versus GM. { P,0.05, {{
P,0.001 versus MNIM. The significance was determined by ANOVA followed by Fisher’s LSD post hoc test. (C) Immunocytochemistry of BrdU
incorporation (red) and EGFP (green) in EOH cells cultured in GM, MNIM, and MNIM+GM. (D) Quantitative analysis of BrdU incorporation. Fifty to
150 cells per group were analyzed in randomly chosen fields. The bars represent mean6SEM of at least three independent experiments. * P,0.05
versus GM. The significance was determined by ANOVA followed by Fisher’s LSD post hoc test.
doi:10.1371/journal.pone.0035244.g003
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ment. These data suggest that genetic modification of hMSCs to
express Olig2 and Hb9 renders them capable of inducing MN
differentiation only in the presence of MNIM.
Our study demonstrates that hMSCs can be induced into
functional MN-like cells after a 2-step process, including ectopic
expression of transcription factors and MNIM treatment. MNIM-
EOH cells have an increased expression of mature neuronal and
MN-specific markers, including NeuN, NF-M, ChAT, and Islet-1.
MNIM-EOH cells can also form functional connections with
C2C12 myotubes. Based on the electrophysiological properties of
the induced EOH cells, our data demonstrate that MNIM-EOH
cells are clearly reprogrammed and directed toward a MN-like
lineage. For example, although Na+ current recorded in MNIM-
EOH cells is small, its amplitude can be estimated at ,300 pA in
voltage of 210 mV. This 300 pA inward current is thought to be
enough to generate the action potential, although Na+ current of
MNIM-EOH cells is smaller than Na+ current of neurons. In
current clamp mode, 200 pA current injection can induce the
depolarization and single action potential. Thus, small Na+
current of MNIM-EOH cells can induce the action potential-like
excitability, not the fast action potential of neuron.
Figure 4. Excitable properties of MNIM-treated EOH cells. Representative perforated patch clamp recordings from uninduced EOH cells (A)o r
MNIM-EOH cells (B). The cells were held at 260 mV and currents elicited by stepping from 290 to +30 mV in 10 mV steps. MNIM-EOH cells express
robust outward K+ currents but very small inward Na+ currents (filled upright triangle). Current injection (200 pA, 100 ms) induced action potential in
MNIM-EOH cells, not in uninduced EOH cells. (C) Resting membrane potential in uninduced EOH cells and MNIM-EOH cells. The bars represent mean
6 SEM. * P,0.05. The significance was determined by Student’s t test.
doi:10.1371/journal.pone.0035244.g004
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maintain neuron-like phenotype even at 2 days after trans-
plantation into the injured spinal cord slice. One of the major
hurdles with neuronal replacement therapy is the integration of
transplanted neurons into the existing neural networks. Therefore,
further studies are needed to confirm whether these survived
cells can be possibly integrated into pre-existing neural networks
in the injured spinal cord slice while maintaining expression of
neuronal and MN-specific markers. It will also be interesting to
investigate whether these cells can innervate appropriate
peripheral targets to replace missing or degenerated MNs in
the animal model of MN diseases, such as ALS.
Although we ectopically expressed Olig2 and Hb9 in hMSCs,
the transdifferentiation potential seems to depend on each
subpopulation of hMSCs. This may explain why it still remains
controversial whether MSCs can transdifferentiate into functional
neurons [11,12,43,44]. Several recent studies have reported that
a subpopulation of MSCs in bone marrow may originate from
neural crest stem cells (NCSCs) during development [45,46].
NCSCs are known to have the potential to differentiate into
neurons, glial cells, and myofibroblasts [47,48]. Thus, it has been
Figure 5. MNIM-EOH cells can trigger AChR clustering and form functional connections with cocultured myotubes. (A) Fluorescence
images of MNIM-EOH cells at 1 day after cocultured with C2C12 myotubes. a-BTX staining revealed AChR clustering on C2C12 muscle fibers. Confocal
Z-stack imaging, in a line through the region of apparent colocalization, confirmed EGFP+ axons in close proximity to AChRs (arrows). Scale bars:
10 mm. (B) End-plate currents (EPCs) were recorded from myotubes located in close proximity to MNIM-EOH cells. EPCs were blocked from the same
cell after application of 15 mM pancuronium. However, after washing out of pancuronium, EPCs could be recorded again. The bars represent
mean6SEM. * P,0.05. The significance was determined by Student’s t test.
doi:10.1371/journal.pone.0035244.g005
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MSCs may reflect the presence of NCSCs of the bone marrow
[45,46]. In our previous study, we also observed that several neural
crest cell markers were highly expressed in control hMSCs and
that p75NTR mRNA levels were highly induced in response to
serum [37]. Further studies are needed to determine whether these
molecular changes occurred specifically within a subpopulation of
hMSCs with a neural crest origin. Therefore, identification of this
subpopulation with high capacity to differentiate into neurons will
enhance the potential of hMSC administration as a therapeutic
strategy to treat degenerative MN diseases.
In summary, we demonstrate that hMSCs can be induced into
functional MN-like cells in a 2-step process, including ectopic
expression of transcription factors and an optimized induction
protocol. The induced cells have marked expression of MN
markers and the excitable properties of neurons. They can form
functional connections with muscle fibers in vitro and maintain
their neuron-like morphology and neuronal marker expression
even at 2 days after transplantation into the injured spinal cord
slice. Neuronal replacement of missing or degenerated neurons
will likely enhance recovery from degenerative MN diseases.
Therefore, our study provides and tests the potential of hMSC
administration as a therapeutic strategy to treat degenerative MN
diseases.
Materials and Methods
Human Mesenchymal Stem Cell Culture
Cryopreserved adult hMSCs (PoieticsH normal human mesen-
chymal stem cells) were purchased from Cambrex (Walkersville,
MD). hMSCs (passages 4 through 12) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM)-low glucose (Hyclone, Logan,
UT) containing 10% fetal bovine serum (FBS; Gibco-BRL,
Carlsbad, CA) at 37uC with 5% CO2.
Expression Vector Construction and Infection
A full-length mouse Olig2 cDNA fragment (GenBank Accession
number: NM_016967) was constructed by inserting the EcoRI-
EcoRV digested gene fragment into an EcoRI-PmeI-digested
lentiviral vector, pgk EGFP-mCMV-IRESpuro (pLentiM1.41;
Macrogen Inc., Seoul, Korea) (EO). The full-length mouse Hb9
cDNA (GenBank Accession number: NM_019944) was treated
with T4 polymerase to produce blunt ends, and the blunt-ended
Hb9 cDNA was inserted into the pLentiM1.41 (EH). For the
coexpression of Olig2 and Hb9, Olig2 and Hb9 cDNA fragments
were cloned into the multicloning sites of the retroviral vector
plasmid EGFPBsd-CLCBC4 (EOH). The construct was confirmed
through multiple and combined digestions, and the nucleotide
sequence of the construct was verified by DNA sequencing. Viral
particles were produced by transfecting the retrovirus packaging
cell line 293T with each plasmid using Lipofectamine (Invitrogen,
Carlsbad, CA), and supernatants containing viral particles were
harvested 72 hours after incubation. For viral transduction,
hMSCs were incubated for 6 hours with the viral supernatant
(3–5610
6 particles/ml) containing polybrene (1 mg/ml, Sigma-
Aldrich, St. Louis, MO), followed by a medium change.
MN Induction of Human Mesenchymal Stem Cells
Subconfluent hMSCs were incubated in growth medium with
1m Mb-mercaptoethanol (Sigma-Aldrich) for 24 hours and were
subsequently treated with 2 mM b-mercaptoethanol. After
3 hours, cultures were transferred to growth medium containing
1 mM retinoic acid (RA; Sigma-Aldrich) and 5 mM forskolin (FSK;
Sigma-Aldrich). At day 3, the cultures were maintained in growth
medium supplemented with 1 mM RA, 5 mM FSK and 10 ng/ml
recombinant human basic-fibroblast growth factor (bFGF; Pepro-
tech, Rocky Hill, NJ). After an additional 4–6 days of culture, with
media changes every 2 days, the cells were induced in the presence
of 1 mM RA, 5 mM FSK, 10 ng/ml bFGF and 200 ng/ml
recombinant human sonic hedgehog (SHH; R&D Systems,
Hornby, Ontario, Canada).
Reverse Transcription-polymerase Chain Reaction
RNA was extracted using the TRIzol reagent (Invitrogen),
followed by DNase treatment and then reverse transcription to
cDNA using M-MLV reverse transcriptase (Invitrogen). Aliquots
of cDNA (200 ng) were used as templates in the PCR reactions
(50 ml), containing 200 nM dNTPs, 100 pM of each primer pair,
and 0.5 U of Taq DNA polymerase (Takara Bio, Tokyo). Table 2
displays the primer probe sets used for the PCR reactions.
Products were visualized by electrophoresis using 2% agarose gel.
Figure 6. Ex vivo assessment of EOH cells or MNIM-EOH cells
after transplantation into the spinal cord slice culture. Confocal
images of uninduced EOH cells (green) (A-C) or MNIM-EOH cells (green)
(D-F) at 2 days after transplantation into the ventral horn area (vh) of
a spinal cord slice. (B) and (E) are a higher magnification of (A) and (D),
respectively. (C) Confocal image of transplanted EOH cells with
a flattened and symmetrical fibroblast-like morphology. (F) Confocal
image of transplanted MNIM-EOH cells with a neuron-like morphology.
Scale bars: 100 mm.
doi:10.1371/journal.pone.0035244.g006
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of transcript abundance, based on b-actin expression.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde, permeabilized and
blocked with 0.2% Triton X-100 and 3% bovine serum albumin
(BSA) in phosphate-buffered saline (PBS). Cells were incubated
overnight at 4uC with the following primary antibodies: mouse
monoclonal anti-NeuN, 1:500 (Chemicon, Temecula, CA), rabbit
polyclonal anti-neurofilament-M (NF-M), 1:500 (Chemicon),
mouse monoclonal anti-choline acetyltransferase (ChAT), 1:200
(Chemicon), and mouse monoclonal anti-Islet-1, 1:10 (Develop-
mental Studies Hybridoma Bank [DSBH], Iowa City), mouse
monoclonal anti-Hb9, 1:50 (DSBH), and rabbit polyclonal anti-
Olig2, 1:5,000 (kindly provided by Dr. Charles D. Stiles, Harvard
Medical School, Boston, MA). After washing with PBS, cells were
incubated with the following secondary antibodies: Alexa Fluor
546 anti-mouse IgG (Invitrogen), Alexa Fluor 546 anti-rabbit IgG
(Invitrogen), and anti-rabbit Cy5 (Jackson Laboratory, West
Grove, PA). Cells were coverslipped with mounting medium
(Dako, Glostrup, Denmark), and immunoreactive cells were
analyzed under a laser-scanning confocal microscope (Olympus,
Tokyo).
Bromodeoxyuridine Incorporation
The hMSCs were incubated with 10 mM bromodeoxyuridine
(BrdU; Sigma-Aldrich) for 24 hours and fixed with 4% para-
formaldehyde. The DNA was then denatured with 2 N HCl for
30 minutes at 37uC, and the reaction was neutralized with 0.1 M
sodium borate (pH 8.5) for 10 minutes at room temperature. The
rest of the protocol was a standard immunocytochemistry. Mouse
monoclonal anti-BrdU, 1:200 (Chemicon) was used as the primary
antibody.
Myotube Co-culture
Undifferentiated mouse myoblast C2C12 cells (American Type
Culture Collection, Manassas, VA) were maintained in DMEM
with 10% FBS, penicillin and streptomycin. The C2C12 cells were
plated onto glass coverslips in six-well plates (2610
5 cells/35-mm
well) in maintaining medium. After 2 days, C2C12 cells were
Figure 7. MNIM-EOH cells express mature neuronal/MN markers after transplanted into the injured spinal cord slice culture.
Confocal microscopy analysis of MNIM-EOH cells (green) immunostained with anti-NeuN (red) (A), anti-NF-M (red) (B), and anti-ChAT (red) (C)
antibodies. In the slices, 37 of 472 EGFP+ cells were NeuN+, 20 of 316 EGFP+ cells were NF-M+, and 14 of 469 EGFP+ cells were ChAT+. Colocalization
of EGFP and NeuN, NF-M, or ChAT in a single cell was confirmed by z-axis stack analysis. At least 4 slices were analyzed. Scale bars: 50 mm.
doi:10.1371/journal.pone.0035244.g007
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penicillin and streptomycin for 3 additional days. Differentiated
C2C12 myotubes were co-cultured with MNIM-EOH cells for
24 hours. Immunocytochemistry were performed with rhoda-
mine-conjugated a-bungarotoxin, 1:1000 (a-BTX, Molecular
Probes, Eugene, OR). Optical sections (1.0-mm) were collected
as stacked z-dimension images, which were inspected orthogonally
in both the horizontal and vertical planes.
Electrophysiological Recordings
MNIM-EOH cells were studied using the perforated patch
clamp technique. Patch pipettes were pulled from borosilicate
capillaries (PP-83 puller, Narishige, Tokyo, Japan) with resistances
of 4–5 MV when filled with pipette solution (in mM: 126 K-
gluconate, 10 NaCl, 1 MgCl2, 0.5 EGTA, 2 NaATP,
0.1 MgGTP. pH adjusted to 7.3 with KOH). In all experiments,
the external solution consisted of 145 mM NaCl, 5 mM KCl,
2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES pH 7.4, and
10 mM glucose. The membrane currents were recorded in the
nystatin-perforated patch configuration using an EPC-9 amplifier
and Pulse 8.30 software (both from HEKA, Lamprecht,
Germany). Nystatin (Sigma-Aldrich) was employed as the perme-
able agent in the perforated patch-clamped cells to form voltage-
insensitive ion pores in the membrane patch that are somewhat
selective for cations over anions but are impermeable to
multivalent ions or molecules .0.8 nm in diameter. Nystatin
was dissolved in dimethyl sulfoxide (DMSO) at 50 mg/ml and
then added to the internal solution to yield a final nystatin
concentration of 200 mg/ml. The series resistances in perforated
patch-clamping neurons were within 30–45 MV. The cells were
held at 260 mV and currents were elicited by stepping from 290
to +30 mV in 10 mV steps. The recording chamber was gravity
superfused with external solution at ,10 ml/min. The data were
digitized at a sampling rate of 3 kHz and were filtered at 10 kHz.
Data files were analyzed using Origin 4.1.
Whole-cell Recordings of Muscle Fibers
Single myotubes near MNIM-EOH cells were visually identified
using a fixed-stage microscope (BX50WI, Olympus, Japan) with
Nomarski optics and a 406water-immersion objective. Myotubes
with stable resting membrane potentials (Vm) between -50 and
260 mV were included in the analysis. Postsynaptic end-plate
currents (EPCs) were amplified via an EPC-9 amplifier and Pulse
8.30 software. Signals were analyzed off-line using the Mini
Analysis Program (Synaptosoft, Decatur, GA, http://www.
synaptosoft.com).
Organotypic Spinal Cord Slice Culture
Ethics statement. This study was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Institutional Animal
Care and Use Committee of Seoul National University (Permit
Number: SNU-091120-2). All surgery was performed under
avertin anesthesia, and all efforts were made to minimize suffering.
Organotypic slice cultures were prepared as previously de-
scribed [37,39]. Sixteen-day-old Sprague-Dawley rats were
anaesthetized with avertin, and their lumbar spinal cords were
collected under sterile conditions. Nerve roots and excess
connective tissue were removed in cold Hank’s balanced salt
solution (HBSS; Gibco-BRL) containing 6.4 mg/ml glucose. The
spinal cords were cut into 400-mm slices with a McIlwain tissue
chopper (Mickle Laboratory Engineering, Gomshall, Surrey, UK).
Four slices were carefully placed on a membrane insert (Millicell-
CM; Millipore, Billerica, MA) and placed into a 6-well plate with 1
ml of culture media consisting of 50% Eagle’s minimum essential
medium (Gibco-BRL), 25% HBSS, 25% horse serum, 6.4 mg/ml
glucose and 20 mM HEPES (Sigma-Aldrich). Slices were cultured
at 37uC with 5% CO2, and the media were changed twice per
week.
hMSC Transplantation into the Lysolecithin-treated
Spinal Cord Slice Culture
At 7 days in vitro (DIV), slices were treated with 0.5 mg/ml
lysophosphatidylcholine (lysolecithin; Sigma-Aldrich) for 17 hours
at 37uC as previously described [37]. For transplantation, EOH
cells or MNIM-EOH cells were trypsinized and centrifuged at
2,000 g for 3 minutes. The pellet was resuspended in PBS, and
cells (6610
3 cells/1 ml) were transplanted directly into the area of
the ventral horn (VH) of each spinal cord slice using aspirator tube
assembly for microcapillary pipette (Sigma-Aldrich). After 2-
6 days in culture, cells on the slices were analyzed by confocal
microscopy after processed for immunofluorescence.
Table 2. Polymerase chain reaction primer pairs.
Gene Accession number Primer sequence Predicted size (base pairs) Anneal (uC) Cycle no.
Olig2 NM_005806 59-aaggaggcagtggcttcaagtc-39 315 60 35
59-cgctcaccagtcgcttcatc -39
Hb9 NG_013212 59-gcaggcggcgctctac-39 258 56 35
59-ttccccaggaggttcgac-39
NF-M BC096757 59-tgggaaatggctcgtcatttg-39 333 57 35
59-cttcatggaaacggccaattc-39
Islet-1 NM_002202 59-gcagcatcggcttcagcaag-39 356 60 35
59-gtagcaggtccgcaaggtg-39
VAChT U10554 59-tggcgctgttactggcaac-39 249 60 35
59-tcttcacgtcttcgctctc-39
b-actin NM_001101 59-ccacgaaactaccttcaactcc-39 270 55 30
59-tcatactcctgctgcttgctgatcc-39
doi:10.1371/journal.pone.0035244.t002
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Data were analyzed using Student’s t test or one-way analysis of
variance (ANOVA) followed by post hoc comparisons with
Fisher’s protected least significant difference (LSD) test. RT-
PCR results were analyzed using the Kruskal-Wallis and Mann-
Whitney tests. The data were evaluated using the language R (R
Development Core Team 2010) and were expressed as the
mean6standard error of mean (SEM). Probability (P) values
,0.05 were considered statistically significant.
Supporting Information
Figure S1 Doubling time of uninduced EOH cells. We
employed regression with ‘‘exponential rise to maximum’’ type, as
y=y o + b(1 – e
–ax), where yo is the intercept, a is the slope between
x and y, and b is the maximum y value. According to the
estimations in 99% confidence (P , 0.01), Ncell at t=0
corresponds to 2128 and the growth rate (i.e., number of
doublings that occur per unit of time) results in 0.0139. Note
that our data can be well fitted as Ncell=2128+6469 (1 –
e
20.01396time). The doubling time of EOH cells is calculated as
ln2/0.0139=49.87 hr.
(TIF)
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